300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Film
Oil and Gas
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Recruiting
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Web3
Medical
Theatre
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
LATAM
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Algeria
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Tanarra Capital, VC Fund

Tanarra Capital

VC Fund

Melbourne, Australia

Tanarra Capital is a VC fund in Melbourne focused on Artificial Intelligence and Medical. Tanarra is an Australian family office investment and advisory firm. Tanarra invests in a wide range of early-stage ventures, private and public companies in Australia and around the world. Current early-stage investments include Pexip, a world-leading video technology company based in Oslo; Genomics, an Oxford-based business using geneticanalysis to improve pharma R&D investment returns; and Oxford PV, a new generation solar photovoltaic cell technology. Previous investments have included Business Spectator, the business media publication founded by well-known Australian journalist Alan Kohler, which was later acquired by News Corporation.

Total investments:
10
Last investment:
Lead investor:
10%
Fund size:
$217M
Last fund:

Last updated:

Industries Tanarra Capital invests in

Artificial IntelligenceMedicalRoboticsSoftwareBiopharma

Stages Tanarra Capital invests in

SeedSeries ASeries BPre-SeedVenture - Series Unknown

Countries Tanarra Capital invests in

United KingdomHong Kong

Round sizes

Seed $3.7M–$7.9MSeries A $9.3M–$13MSeries B $9.1M–$33M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$3.7M–$7.9M
Series A
$9.3M–$13M
Series B
$9.1M–$33M

Investment Focus

Industry

  • Artificial Intelligence 3 (30%)
  • Medical 2 (20%)
  • Robotics 2 (20%)
  • Software 2 (20%)
  • Biopharma 2 (20%)
See all 23 industries →

Stage

  • Seed 3 (30%)
  • Series A 2 (20%)
  • Series B 2 (20%)
  • Pre-Seed 1 (10%)
  • Venture - Series Unknown 1 (10%)

Country

  • United Kingdom 5 (50%)
  • Hong Kong 1 (10%)

Team

NameTitleInvestmentsLinksEmail
John Wylie
John Wylie CEO and Founder
CEO and Founder Total investments: 0
Find email
Maja Sliwinski
Maja Sliwinski Investment Director
Investment Director Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment $30M / Series B / May 21, 2026
OXECO designs, develops and manufactures surface treatments for composites and engineering plastics. $10.5M / Venture - Series Unknown / Jun 07, 2022
August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment $9.3M / Series A / Sep 10, 2020
Fraction is a dynamic and rapidly growing company. Seed / Jan 01, 2020
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagramThey will lead the way through this challenge, using their expertise and experience to unleash the potential ofgenomics and set the standards by which organisations and patients can benefit from genomic data. $9.1M / Series B / Dec 09, 2018
At Animal Dynamics they know that nature’s evolved designs are more efficient, elegant and powerful than anything yet built by man. However, the last decade has seen revolutions in analytical technology that allow us to evaluate high-performance animals to a previously unachievable degree, and use cutting-edge science to understand the fundamentalmechanisms underlying this performance.AD does not simply attempt to replicate the high-performance natural designs, but marries fine-engineering skills with a deep understanding of the fundamental mechanisms, to produce revolutionary machines that will change the shape of the future, taking inspiration from their environment in order to protect it, and capable of performance beyond anything currently found in nature or engineering. $7.9M / Seed / Oct 09, 2018
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagramThey will lead the way through this challenge, using their expertise and experience to unleash the potential ofgenomics and set the standards by which organisations and patients can benefit from genomic data. $32.5M / Series B / Aug 30, 2018
August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment $3.7M / Seed / Jun 20, 2018
Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic. $900K / Pre-Seed / Jun 01, 2018
Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagshipproduct, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency. $13.4M / Series A / May 22, 2018

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Film
Oil and Gas
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Recruiting
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Web3
Medical
Theatre
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
LATAM
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Algeria
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Tanarra Capital invest in?

Tanarra Capital invests primarily in Artificial Intelligence, Medical and Robotics startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Tanarra Capital's check size?

Tanarra Capital typically joins rounds of $3.7M–$7.9M at Seed, $9.3M–$13M at Series A and $9.1M–$33M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tanarra Capital participates in.

How do I contact Tanarra Capital?

Public channels for Tanarra Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Tanarra Capital?

The team at Tanarra Capital includes John Wylie (CEO and Founder) and Maja Sliwinski (Investment Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Tanarra Capital Tanarra Capital Find emails